Shanghai Ennova Biopharmaceutical Co. Ltd. has identified condensed ring compounds acting as ATP-dependent 6-phosphofructokinase, liver type (PFKL) activators reported to be useful for the treatment of cancer, autoimmune disease, inflammatory disorders, lung diseases, metabolic diseases, sepsis and thrombosis.